MAPT and Alzheimer disease: Deficiency of NLRP3 has been shown to prevent disease progression in both APP- and tau-transgenic mice (Heneka et al., 2013; Ising et al., 2019; Jiang et al., 2021); however, the effects of NLRP3 on microvascular circulation in AD brains were not investigated.